Skip to content
DataLookout
Menu

VIGILANTNCT07177339

eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary endpoints: details revised at 1 of 1 entry Show 5 more changesShow less
    • Eligibility criteria shortened, about 3 words
    • Trial sites expanded: 121 → 293 locations
    • Primary completion date: Apr 30, 2029 to Apr 2, 2029
    • Study completion date: Jun 8, 2029 to Jun 4, 2029
    • Secondary endpoints: details revised at 3 of 3 entries
  2. Minor Trial sites expanded: 6 → 121 locations
    • Primary completion moved earlier from Nov 2, 2029 to Apr 30, 2029
    • Study completion moved earlier from Dec 14, 2029 to Jun 8, 2029
    v4
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 6
    • Primary completion date: Oct 19, 2029 to Nov 2, 2029
    v3
  4. Minor Primary completion date: Nov 16, 2029 to Oct 19, 2029
    • Study completion date: Jan 11, 2030 to Dec 14, 2029
    • Start date: Nov 17, 2025 to Oct 20, 2025
    v2
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Annualized Rate of Moderate/Severe Exacerbations
Timeframe: From Baseline Up to Week 156

Secondary (3)

Time to First Moderate/Severe Exacerbation
Change from Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score at Week 52
Change from Baseline in Evaluating Respiratory Symptoms (E-RS): COPD Total Score at Week 52

Arms and interventions

DepemokimabExperimental

Participants with Chronic Obstructive Pulmonary Disorder (COPD) with Type 2 inflammation will receive Depemokimab in combination with existing Standard of Care (SoC).

PlaceboExperimental

Participants with COPD with Type 2 inflammation will receive matching Placebo in combination with existing SoC.

Drugs: Depemokimab, Placebo

Sites

293 sites in 25 countries

United States 75, China 47, Japan 36, Germany 20, Argentina 14, United Kingdom 12, Spain 11, Bulgaria 9, Israel 8, South Korea 8, France 7, Greece 6, Poland 6, Canada 5, Denmark 4, Belgium 3, Brazil 3, Italy 3, New Zealand 3, Romania 3, Taiwan 3, Australia 2, Hungary 2, Netherlands 2, Chile 1